Effects of Intranasal Oxytocin and Vasopressin on Social Behavior

Not Applicable

• Conditions: Healthy
• Interventions: Drug: Arginine Vasopressin; Drug: placebo; Drug: Oxytocin

• Registration Number: NCT01296269
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

The purpose of this study is to investigate the role of a one-time intranasal administration of the oxytocin, vasopressin, or placebo on prosocial decision making such as cooperation and altruism in a healthy population of student controls.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-02-03
• Study First Submitted QC: 2011-02-14
• Study First Posted: 2011-02-15
• Status Verified: 2011-04
• Study Start: 2011-04
• Last Update Submitted: 2011-04-07
• Last Update Posted: 2011-04-08
• Primary Completion: 2012-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• healthy controls

Exclusion Criteria

• Past or present psychiatric, neurological, endocrinological or severe chronic medical illness.
• Use of medications or drugs that would interfere with study results. This includes steroids, medications for psychiatric symptoms like anxiety or depression, stimulants, and medications for high blood pressure. Participants will be asked to tell the investigators of any medications or drugs that they are taking. The investigators will consider the drug interactions with oxytocin and vasopressin prior to study, and participants will not be able to participate in the study if the drug interactions could be dangerous.
• history of drug or alcohol addiction
• Pregnancy or Nursing Status: Because of the risk to an unborn fetus or infant, women who are pregnant or nursing are excluded from this protocol. All females will have a pregnancy test performed no more than 24 hours before each drug administration and will not be able to participate if the pregnancy test is positive.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Vasopressin	Arginine Vasopressin	vasopressin condition
placebo	placebo	-
oxytocin	Oxytocin	oxytocin condition (syntocinon)

Primary Outcome Measures

Name	Time	Method
allocations of monetary units	approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo	Participants will make decisions regarding the allocation of monetary units between themselves and other participants. We will measure the quantity of monetary units kept for themselves vs. given to other participants

Secondary Outcome Measures

Name	Time	Method
mood as measured via the visual analog scale	approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo

Trial Locations

Locations (1)

Hadassah University Medical Organization; 🇮🇱 Jerusalem, Israel